Cuixia Chu
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Peroxisome Proliferator-Activated Receptors, Cardiac electrophysiology and arrhythmias, Cardiac Fibrosis and Remodeling, Heart Failure Treatment and Management, Diabetes Treatment and Management
Most-Cited Works
- → Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db Mice(2006)80 cited
- → Myocardial Oxygenation During High Work States in Hearts With Postinfarction Remodeling(1999)76 cited
- → Delayed Reperfusion Alters Matrix Metalloproteinase Activity and Fibronectin mRNA Expression in the Infarct Zone of the Ligated Rat Heart(1997)58 cited
- → Pathophysiologic aspects of end-stage heart failure(1995)51 cited
- → Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119(2014)45 cited
- → Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists(2008)37 cited
- → Design, synthesis and structure–activity relationships of azole acids as novel, potent dual PPAR α/γ agonists(2009)35 cited
- → Post-infarction myocardial remodelling: Why does it happen?(1995)23 cited
- → Compensatory and maladaptive responses to cardiac dysfunction(1994)19 cited
- → Effect of Delayed Intervention with ACE-inhibitor Therapy on Myocyte Hypertrophy and Growth of the Cardiac Interstitium in the Rat Model of Myocardial Infarction(1997)19 cited